BioAsset

Insights / All articles

Research

Atavistik Bio: $160M to Drug the Undruggable and Cure a Rare Blood Disorder

By Jingqiu Tian, Research Analyst at BioAsset · 5 slides

Atavistik Bio, a biotechnology startup developing allosteric small-molecule therapeutics, has secured $160 million in Series B funding as of March 2026. The money will support ATV-1601, its drug for a rare bleeding disorder called hereditary hemorrhagic telangiectasia (HHT), along with a second drug for myeloproliferative neoplasms.

A different way into the protein

Atavistik focuses on precision allosteric therapeutics. Despite significant advances in drug discovery, approximately 90% of disease-causing proteins are not properly drugged, because they lack traditional binding sites. Atavistik develops drugs that target alternative sites on those proteins, known as allosteric sites.

A protein’s function is largely determined by the shape of its active site. Allosteric sites are other sites on the protein that, when bound by a molecule, can change the shape of the active site and so alter the protein’s function.

To develop these drugs, the company first identifies functional sites on a proprietary platform, then further engineers the drug using a combination of wet lab work and computation. Bryan E. Stuart is the chief executive officer.

ATV-1601 and HHT

ATV-1601 is one of the allosteric drugs Atavistik has developed, and it is designed to treat HHT, a severe bleeding disorder that affects 1.6 million people globally. Its target is AKT1, an enzyme that regulates the function of the endothelial cells that line blood vessels. In HHT, genetic mutations spur AKT overactivation and cause abnormal blood vessels to form, leading to bleeds, anaemia and other problems.

ATV-1601 is taken orally and selectively inhibits AKT1. By blocking AKT1 activity, the drug broadly addresses the mutations that cause the disease and so tackles the root cause of HHT. Its precision also makes it more tolerable than pan-AKT inhibitors. It spares the related variants of AKT, which prevents toxicity and allows long-term use.

The Series B

In December 2025, Atavistik announced that it had raised $120 million in Series B financing. The round was led by Nextech Invest and The Column Group, with existing investor Lux Capital and new investor Regeneron Ventures participating. In March, the company announced an extension of the round with an infusion of $40 million from RA Capital Management.

The financing will be used to advance ATV-1601 and the company’s drug for myeloproliferative neoplasms (MPNs), a V617F mutant-selective JAK inhibitor. The company’s pipeline shows ATV-1601 at the clinical stage for HHT and vascular malformations and the MPN program in lead optimization. It also lists an oncology partnership with Pfizer, on an undisclosed target, at the discovery stage.

Why it looks promising

ATV-1601 is one of Atavistik’s most promising drugs so far. It is currently in clinical trials, which points to a potentially promising future in treating HHT.

There are currently no highly effective treatments for HHT. Some of the current treatments are pan-AKT inhibitors, which target a family of AKT proteins, and that broad targeting leads to potential toxicity. The specificity of ATV-1601 sidesteps the toxicity issue and allows for long-term use, which makes it a highly promising drug.

The way the company works matters too. By using proprietary platforms to identify protein target sites, then a combination of computation and wet lab work to engineer the drug, Atavistik has been able to develop multiple promising drugs. This method brings together multidisciplinary research and some of the most advanced technologies available, following the framework used by top pharmaceutical companies. Allosteric small-molecule therapeutics, specifically, show a very promising future.

This article is the text version of a BioAsset slide post. See the original slides on bioasset.info.